26 min listen
Precision Pioneers EP 3: CEO of Faze Medicines, Phil Vickers on 'Running toward challenges' in precision medicine development
Precision Pioneers EP 3: CEO of Faze Medicines, Phil Vickers on 'Running toward challenges' in precision medicine development
ratings:
Length:
57 minutes
Released:
Apr 7, 2021
Format:
Podcast episode
Description
Continuing with our mini series of Precision Pioneers, Patrick is joined by Phil Vickers, President and CEO at Faze Medicines. Phil discusses his career, including his time with companies such as Merck and Shire Pharmaceuticals.
Topics discussed include:
* The differences between drug development in common and rare disease
* The unique and patient-centric approach to rare disease research at Shire
* How genomics has impacted drug development in the past 20 years
* How to balance affordability of new medicines with company profitability and continued R&D investment
* The role of 'platforms' in drug development, including both technology platforms and 'knowledge' platforms
Topics discussed include:
* The differences between drug development in common and rare disease
* The unique and patient-centric approach to rare disease research at Shire
* How genomics has impacted drug development in the past 20 years
* How to balance affordability of new medicines with company profitability and continued R&D investment
* The role of 'platforms' in drug development, including both technology platforms and 'knowledge' platforms
Released:
Apr 7, 2021
Format:
Podcast episode
Titles in the series (100)
EP 5 Could Weed Killer Cure This Rare Disease (Alkaptonuria)?: We talk to Nick Sireau (co-founder of Findacure and chairman of the AKU society) about his two sons, who were both born with Alkaptonuria which is an ultra-rare genetic condition that causes the bone's surface to turn black and corrode. Nick... by The Genetics Podcast